Magnesium

Magnesium is an essential dietary mineral with a mechanistic doorway into mood: it is an endogenous modulator of the NMDA glutamate receptor, and it is commonly under-replete in modern diets and in depressed populations. Magnesium is the fourth most abundant cation in the body, a cofactor for over 300 enzymes including those of ATP metabolism; dietary sources are leafy greens, nuts, legumes, and whole grains, all diminished by food refining.

Its evidence base shares a characteristic shape — biologically compelling, with positive but small and heterogeneous trials, strongest where deficiency is present — that will be familiar from vitamin D and the one-carbon (methylation) cluster, and that it shares with its companion mineral, zinc.

Proposed Mechanism

Magnesium sits in the NMDA receptor channel as a voltage-dependent block — the same block that ketamine and other NMDA antagonists relieve or mimic. By tonically dampening NMDA-mediated calcium influx, adequate magnesium constrains glutamatergic excitotoxicity; deficiency disinhibits NMDA signaling. This places magnesium conceptually adjacent to the rapid-acting glutamatergic antidepressants, though it is a far weaker and less targeted intervention.

Magnesium also inhibits glycogen synthase kinase-3 (GSK-3) — a target shared with lithium and implicated in several antidepressants' downstream action — regulates HPA-axis reactivity and cortisol, and supports mitochondrial ATP production.

Evidence Base

A 2023 meta-analysis (Moabedi et al.) of seven RCTs in adults with depressive disorder reported a striking pooled effect — SMD ≈ −0.92 — but the honest reading lives in the fine print: only ~325 total participants across small, heterogeneous, and mostly low-quality trials, with wide confidence intervals. This is a textbook case of a large effect size with low certainty, where the magnitude is as likely to reflect small-study bias as a true large benefit. The widely cited Tarleton (2017) trial — immediate-release magnesium chloride producing rapid symptom improvement — was open-label and unblinded. Magnesium is mechanistically attractive and the signal is directionally consistent, but the evidence cannot yet support confident effect-size claims.

The honest synthesis: magnesium is reasonable to assess and correct in depressed patients, and has a plausible, NMDA-anchored rationale plus modest trial support. It does not have evidence adequate to claim a robust standalone antidepressant effect, and the eye-catching effect size should be read with its sample-size and blinding limitations firmly attached.

Who Might Benefit / Indications

The clearest candidates are depressed patients with dietary inadequacy or conditions predisposing to deficiency — magnesium depletion with PPI or diuretic use, alcohol use, poorly controlled diabetes, or GI malabsorption. Magnesium is a defensible adjunct, particularly where there is comorbid insomnia, anxiety, or constipation that its side-effect profile might incidentally help. It should not displace first-line treatment.

Formulation, Dosing & Bioavailability

Form matters for tolerability and absorption. Glycinate, citrate, malate, and threonate are better absorbed and gentler than oxide, which is poorly bioavailable and the most laxative. Magnesium L-threonate is marketed for CNS penetration with limited human mood data. Typical elemental doses are ~200–400 mg/day; titrate to bowel tolerance (loose stools are the dose-limiting effect).

Safety & Interactions

Magnesium is safe with normal renal function; the common effect is dose-dependent diarrhea. The important caution is renal impairment, where magnesium accumulates and can cause clinically significant hypermagnesemia — avoid or use cautiously and monitor. Magnesium can reduce absorption of oral bisphosphonates, tetracyclines, and fluoroquinolones (separate dosing). It does not interact pharmacodynamically with antidepressants in a hazardous way.

Convergence

Magnesium is among the series' clearest ties to the glutamatergic/NMDA axis and, through it, conceptually adjacent to the rapid-acting antidepressants. Its GSK-3 inhibition rhymes with lithium's mechanism; its HPA effects link to chronic stress; its ATP role to mitochondrial function. Within this series it shares its "measure-and-correct" logic with vitamin D and its antioxidant/glutamate rationale with NAC, and it is the natural companion to zinc.

Caveats

The magnesium literature is the sharpest reminder in this series that effect size and evidence quality are different axes. An SMD near −0.9 reads like a major intervention; sourced from seven small, largely unblinded trials totaling a few hundred patients, it is a hypothesis, not a fact. Magnesium is also entangled in the deficiency-confound that pervades nutritional psychiatry — low levels may be partly a consequence of the poor diet and physiologic stress of being depressed. The defensible stance is modest and clinical: screen for and correct true deficiency, use as a low-risk adjunct with realistic expectations, and do not let an impressive-looking pooled number outrun the trials that produced it.

Bottom Line

Magnesium (~200–400 mg/day of a well-absorbed form, titrated to bowel tolerance; cautious in renal impairment) is a safe, inexpensive, NMDA-relevant mineral worth assessing and correcting in depressed patients, and a reasonable low-risk adjunct — best supported where deficiency exists and as an antidepressant add-on rather than monotherapy. The meta-analytic effect looks large but rests on small, mostly unblinded trials. Correct deficiency diligently; promise modestly.

Key References

1. Moabedi M, et al. Magnesium supplementation beneficially affects depression in adults with depressive disorder: a systematic review and meta-analysis of RCTs. Front Psychiatry. 2023.
2. Tarleton EK, et al. Role of magnesium supplementation in the treatment of depression: a randomized clinical trial. PLoS One. 2017.
3. Eby GA, Eby KL. Rapid recovery from major depression using magnesium treatment. Med Hypotheses. 2006.
4. Poleszak E, et al. NMDA/glutamate mechanism of antidepressant-like action of magnesium. Pharmacol Biochem Behav. 2007.
5. Boyle NB, et al. The effects of magnesium supplementation on subjective anxiety and stress: a systematic review. Nutrients. 2017.
6. Wang J, et al. Zinc, magnesium, selenium and depression: a review of the evidence. Nutrients. 2018.
7. Serefko A, et al. Magnesium in depression. Pharmacol Rep. 2013.
8. Sarris J, Ravindran A, Yatham LN, et al. Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: WFSBP and CANMAT Taskforce. World J Biol Psychiatry. 2022.